<DOC>
	<DOCNO>NCT00002244</DOCNO>
	<brief_summary>The purpose study see safe effective give WF10 adult late-stage HIV disease . WF10 suspect help immune system fight infection slow HIV disease progression .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness WF10 Given Patients With Late-Stage HIV Disease</brief_title>
	<detailed_description>Patients randomize 1 2 treatment group receive 4 IV treatment cycle either WF10 control ( physiological saline solution ) . Patients monitor throughout study : ) clinical progression ; b ) number , duration , cause hospitalization ; c ) quality life ; ) density CD38 antigen CD8+ T cell . Patients receive treatment 11 week continue follow maximum 96 week . During follow-up period , patient evaluate initially Week 18 , Weeks 24 , 36 , 48 . If study continue beyond Week 48 , follow-up visit conduct Weeks 72 96 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have CD4 cell count le 50 cells/mm3 within 14 day prior study entry . Are least 18 year old . Have receive antiHIV drug time past . Agree practice abstinence use effective method birth control , include pill , study . Exclusion Criteria Patients eligible study : Are treated form cancer within 30 day study entry . Have ever receive HIV vaccine . Have receive steroid within 30 day prior study entry . ( Note : Testosterone allow . ) Have receive certain medication , include antiHIV treatment approve FDA . Have participate another WF10 study . Have illness condition might exclude study . Are pregnant breastfeeding . Abuse drug medication . Received blood transfusion within 45 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>tetrachlorodecaoxide</keyword>
</DOC>